banner
 
bar

program

slides
bar
 
 

High Risk Postmenopausal
Osteoporosis

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period June 18, 2012 through June 18, 2014 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all five segments totaling 2 hours and 51 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate..

Estimated Time to Complete Educational Activity

3.0 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances osteoporosis.

Release Date

June 18, 2012

Expiration Date

June 18, 2014

Intended Audience

This program is intended for all rheumatology specialists, endocrinology specialists, osteoporosis specialists, bone metabolism specialists, biologics-focused clinical pharmacists, Internal medicine specialists with osteoporosis clinical focus, and other specialists treating osteoporosis

Registration

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logoSupported by an
Independent Educational Grant
from Amgen.

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity

Disclosure of Conflicts of Interest

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosure

MONE ZAIDI, MD, PhD, FRCP, Hon MD
(Program Chairperson)
Professor of Medicine
Director, The Mount Sinai Bone Program
Mount Sinai School of Medicine
New York, NY

Consultant: GSK
Speaker's Bureau: Amgen
Grant/Research Support: NIH



ROBERTO PACIFICI, MD
Garland Herndon Professor of Medicine
Director, Division of Endocrinology, Metabolism and Lipids
Emory University School of Medicine
Atlanta, GA

Nothing to disclose

STUART L. SILVERMAN, MD, FACP, FACR
Medical Director
Bone Center of Excellence, Cedars-Sinai Medical Center
Clinical Professor of Medicine and Rheumatology
University of California
Los Angeles, CA

Consultant: Amgen, Genentech, Lilly, Novartis, Pfizer/Wyeth
Speaker's Bureau: Amgen, Lilly, Novartis, Pfizer/Wyeth
Grant/Research Support: Lilly, Pfizer/Wyeth

MICHAEL R. McCLUNG, MD
Founding Director
Oregon Osteoporosis Center

Consultant: Amgen, Lilly, Merck, Novartis
Speaker's Bureau: Amgen, Lilly, Novartis, Warner-Chilcott
Research Support: Merck, Amgen

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this educational activity, participants should:

  1. Develop a more rigorous scientific understanding and become more clinically proficient at implementing established and new strategies for treating postmenopausal women with osteoporosis who are at high risk for fracture
  2. Better understand how to risk stratify postmenopausal women with osteoporosis to determine their risk for future fracture based on such factors as history of previous osteoporotic fracture, and other FRAX®-linked features that place them at high risk for fractures
  3. Better understand how to assess treatment failure in postmenopausal women on osteoporosis therapeutic regimens; and, become more clinically proficient at implementing evidence-based strategies, using injectable agents, in patients who are responding sub-optimally to osteoporosis treatment
  4. Become more clinically proficient at evaluating patients whose medication compliance, persistence, and/or regimen adherence are compromised by intolerance and/or adverse side effects to osteoporosis therapy
  5. Become more clinically proficient at aligning approved therapies, including injectable therapies, for postmenopausal osteoporosis with specific clinical profiles based on risk for fractures
  6. Better understand diverse mechanisms of action among osteoporosis treatments, including the basis of action of bisphosponates and RANKL inhibitors and their effects on osteoclast differentiation, activation, and survival
  7. Better identify women at high risk for fracture, and parenteral strategies that have the potential for improving regimen adherence and osteoprotection

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

Actonel
Alendronate
Bisphosphonate
BMD
BMI
Bone
Bone Quality
Macro-architecture
Boniva
Calcitonins
Calcium
Cathepsin K
Denosumab

Estrogen
Estrogen-Progestin Combinations
Evista
Fortical
Fosamax
Fractures
FRAX
HORIZON
Ibandronate
Miacalcin
Micro-architecture
National Osteoporosis

Foundation
NOF
osteopenia
Non-Vertebral
Odanacatib
ODN
Osteoblasts
Osteoclast
Osteoporosis
Prolia
Raloxifene
RANK Ligand
RANKL Inhibitor

Denosumab
Reclast® IV
Remodeling
Risedronate
Sclerosteosis
Sclerostin
SOST
Teriparitide
Trabecular number
Vertebral
Vitamin D
WHO Bone Density Criteria
Osteoporotic
Zoledronic Acid